A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection

Ajit Nair, Prajak Barde, Kasi V Routhu, Swaroop Vakkalanka, RP7214-2101 Study Group
doi: https://doi.org/10.1101/2023.02.08.23285565

Data Availability

The data that support the findings of this study are available from the corresponding author Ajit Nair upon reasonable request.

Back to top
Posted February 08, 2023.
Download PDF
Data/Code
Email
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection
Ajit Nair, Prajak Barde, Kasi V Routhu, Swaroop Vakkalanka, RP7214-2101 Study Group
medRxiv 2023.02.08.23285565; doi: https://doi.org/10.1101/2023.02.08.23285565
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area